Charles Atkinson

Array ( [id] => 5801500 [patent_doc_number] => 20020009776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-01-24 [patent_title] => 'Fibroblast growth factor receptor-like molecules and uses thereof' [patent_app_type] => new [patent_app_number] => 09/815108 [patent_app_country] => US [patent_app_date] => 2001-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 33706 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0009/20020009776.pdf [firstpage_image] =>[orig_patent_app_number] => 09815108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5888570 [patent_doc_number] => 20020012968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-01-31 [patent_title] => 'Novel drosophila tumor necrosis factor class molecule (\"DmTNF\") and variants thereof' [patent_app_type] => new [patent_app_number] => 09/813329 [patent_app_country] => US [patent_app_date] => 2001-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 80166 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0012/20020012968.pdf [firstpage_image] =>[orig_patent_app_number] => 09813329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6711029 [patent_doc_number] => 20030170778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-09-11 [patent_title] => 'Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof' [patent_app_type] => new [patent_app_number] => 09/805456 [patent_app_country] => US [patent_app_date] => 2001-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 24843 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0170/20030170778.pdf [firstpage_image] =>[orig_patent_app_number] => 09805456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6657100 [patent_doc_number] => 20030077818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-04-24 [patent_title] => 'Compositions and methods for targeting interleukin-12 to malignant endothelium' [patent_app_type] => new [patent_app_number] => 09/801485 [patent_app_country] => US [patent_app_date] => 2001-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6426 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0077/20030077818.pdf [firstpage_image] =>[orig_patent_app_number] => 09801485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5801508 [patent_doc_number] => 20020009780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-01-24 [patent_title] => 'Design and discovery of protein based TNF-alpha variants for the treatment of TNF-alpha related disorders' [patent_app_type] => new [patent_app_number] => 09/798789 [patent_app_country] => US [patent_app_date] => 2001-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 26276 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0009/20020009780.pdf [firstpage_image] =>[orig_patent_app_number] => 09798789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6898318 [patent_doc_number] => 20010046483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2001-11-29 [patent_title] => 'Medicaments for manipulating T-cell immune response' [patent_app_type] => new [patent_app_number] => 09/790896 [patent_app_country] => US [patent_app_date] => 2001-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2020 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0046/20010046483.pdf [firstpage_image] =>[orig_patent_app_number] => 09790896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6356569 [patent_doc_number] => 20020058018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-05-16 [patent_title] => 'Novel interleukin-3 and uses thereof' [patent_app_type] => new [patent_app_number] => 09/792246 [patent_app_country] => US [patent_app_date] => 2001-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 52687 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0058/20020058018.pdf [firstpage_image] =>[orig_patent_app_number] => 09792246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7964493 [patent_doc_number] => 06680180 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-01-20 [patent_title] => 'Kv6.2, a voltage-gated potassium channel subunit' [patent_app_type] => B1 [patent_app_number] => 09/719919 [patent_app_country] => US [patent_app_date] => 2001-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 26067 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/680/06680180.pdf [firstpage_image] =>[orig_patent_app_number] => 09719919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1238549 [patent_doc_number] => 06685933 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-02-03 [patent_title] => 'Interferon hybrids' [patent_app_type] => B1 [patent_app_number] => 09/744754 [patent_app_country] => US [patent_app_date] => 2001-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 20902 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/685/06685933.pdf [firstpage_image] =>[orig_patent_app_number] => 09744754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7264707 [patent_doc_number] => 20040151695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-08-05 [patent_title] => 'Expression and secretion vector for human interferon alpha and process for producing human interferon alpha by employing same' [patent_app_type] => new [patent_app_number] => 10/182040 [patent_app_country] => US [patent_app_date] => 2002-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5752 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0151/20040151695.pdf [firstpage_image] =>[orig_patent_app_number] => 10182040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6896409 [patent_doc_number] => 20010027199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2001-10-04 [patent_title] => 'Use of certain drugs for treating nerve root injury' [patent_app_type] => new [patent_app_number] => 09/760810 [patent_app_country] => US [patent_app_date] => 2001-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7612 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0027/20010027199.pdf [firstpage_image] =>[orig_patent_app_number] => 09760810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1508401 [patent_doc_number] => 06441138 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-08-27 [patent_title] => 'Protein which induces interferon- production by immunocompetent cell' [patent_app_type] => B1 [patent_app_number] => 09/752510 [patent_app_country] => US [patent_app_date] => 2001-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10327 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/441/06441138.pdf [firstpage_image] =>[orig_patent_app_number] => 09752510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1155565 [patent_doc_number] => 06762029 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2004-07-13 [patent_title] => 'Methods of identifying agents that modulate P2Y12 receptor activity' [patent_app_type] => B2 [patent_app_number] => 09/745842 [patent_app_country] => US [patent_app_date] => 2000-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 22 [patent_no_of_words] => 20720 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/762/06762029.pdf [firstpage_image] =>[orig_patent_app_number] => 09745842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7064620 [patent_doc_number] => 20010043906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2001-11-22 [patent_title] => 'gamma-IFN liquid-droplet aerosol and method' [patent_app_type] => new [patent_app_number] => 09/747383 [patent_app_country] => US [patent_app_date] => 2000-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 5984 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 165 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0043/20010043906.pdf [firstpage_image] =>[orig_patent_app_number] => 09747383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5889562 [patent_doc_number] => 20020013452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-01-31 [patent_title] => 'Interferon tau compositions and methods of use' [patent_app_type] => new [patent_app_number] => 09/746919 [patent_app_country] => US [patent_app_date] => 2000-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 27384 [patent_no_of_claims] => 95 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0013/20020013452.pdf [firstpage_image] =>[orig_patent_app_number] => 09746919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6063428 [patent_doc_number] => 20020031800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-03-14 [patent_title] => 'Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof' [patent_app_type] => new [patent_app_number] => 09/741149 [patent_app_country] => US [patent_app_date] => 2000-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 24022 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0031/20020031800.pdf [firstpage_image] =>[orig_patent_app_number] => 09741149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1245088 [patent_doc_number] => 06676934 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-01-13 [patent_title] => 'Pharmaceutical composition with tumor necrosis factor A and 2-methoxyestrone-3-0-sulphamate for inhibition of estrone sulphatase' [patent_app_type] => B1 [patent_app_number] => 09/724986 [patent_app_country] => US [patent_app_date] => 2000-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 13 [patent_no_of_words] => 11357 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/676/06676934.pdf [firstpage_image] =>[orig_patent_app_number] => 09724986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1288163 [patent_doc_number] => 06632638 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-10-14 [patent_title] => 'Enhanced solubility of recombinant proteins using Uracil DNA glycosylase inhibitor' [patent_app_type] => B1 [patent_app_number] => 09/715521 [patent_app_country] => US [patent_app_date] => 2000-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10994 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/632/06632638.pdf [firstpage_image] =>[orig_patent_app_number] => 09715521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 473109 [patent_doc_number] => 07230081 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2007-06-12 [patent_title] => 'Interferon gamma conjugates' [patent_app_type] => utility [patent_app_number] => 10/130084 [patent_app_country] => US [patent_app_date] => 2000-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22447 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/230/07230081.pdf [firstpage_image] =>[orig_patent_app_number] => 10130084 [rel_patent_id] =>[rel_patent_doc_number] =>)